Literature DB >> 532711

Malignant hypertension--improving prognosis in a rare disease.

T Gudbrandsson, L Hansson, H Herlitz, L Andrén.   

Abstract

A follow-up was made of 69 patients diagnosed as having malignant hypertension during 1969--76, essential in 26, secondary in 39 and unclassified in 4. A clear male dominance was seen (41 men, 28 women), particularly in the group with essential hypertension (18 men, 8 women). The mortality in this series was less than in previously published series. Thus, the 5-year survival rate was 75% in the patients with essential and 72% in those with secondary hypertension. In part this was due to haemodialysis and renal transplantation. The importance of renal function at the time of diagnosis was evident in this study. In most patients with essential hypertension and serum creatinine levels below 300 mumol/l, renal function could be maintained or improved when antihypertensive treatment was instituted, whereas progression of the renal damage was seen in those with serum creatinine levels above 300 mumol/l in spite of antihypertensive treatment with 3 or more drugs. The incidence of new cases of malignant hypertension tended to decrease during the observation period, particularly as regards essential hypertension.

Entities:  

Mesh:

Year:  1979        PMID: 532711     DOI: 10.1111/j.0954-6820.1979.tb13553.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  12 in total

1.  "Hypertensive emergency": a useful diagnostic category.

Authors:  R B Hickler
Journal:  Am J Public Health       Date:  1988-06       Impact factor: 9.308

Review 2.  The future of pharmacological therapy for risk factor reduction. Hypertension.

Authors:  L Hansson
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 3.  [Malign and refractory hypertension].

Authors:  Georg Schaller; Michael Wolzt
Journal:  Wien Med Wochenschr       Date:  2006-09

4.  Retinal changes in malignant hypertension.

Authors:  E McGregor; C G Isles; J L Jay; A F Lever; G D Murray
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-25

5.  Lack of difference between malignant and accelerated hypertension.

Authors:  M E Ahmed; J M Walker; D G Beevers; M Beevers
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-25

Review 6.  The effects of treatment on target organ damage in hypertensive disease.

Authors:  J Lowenstein
Journal:  Postgrad Med J       Date:  1985-09       Impact factor: 2.401

Review 7.  Hypertensive emergencies and urgencies: definition, recognition, and management.

Authors:  J B Reuler; G J Magarian
Journal:  J Gen Intern Med       Date:  1988 Jan-Feb       Impact factor: 5.128

8.  Renal pathology in hypertension and the effects of treatment.

Authors:  P Kincaid-Smith
Journal:  Br J Clin Pharmacol       Date:  1982-01       Impact factor: 4.335

Review 9.  Rationale for combination therapy.

Authors:  L Hansson
Journal:  Br J Clin Pharmacol       Date:  1987       Impact factor: 4.335

10.  Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin.

Authors:  P Omvik; P Lund-Johansen
Journal:  Cardiovasc Drugs Ther       Date:  1993-04       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.